Novo Nordisk Increases WTT Scholarships
NEW YORK, N.Y. — Novo Nordisk is adding four more scholarships to WTT’s Novo Nordisk Donnelly Awards program, which supports youth tennis players with diabetes. The 2011 program will grant $25,000 in scholarships, including two one-time $5,000 national scholarships and six one-time $2,500 regional scholarships, an increase from two regional scholarships in 2010. The scholarships are awarded to male and female athletes ages 12-21, who have diabetes and play tennis competitively in tournaments or on their school team.
World TeamTennis is currently accepting applications for the 2011 Novo Nordisk Donnelly Awards. Applications must be received byApril 15, 2011, along with two letters of recommendation and a short essay explaining the significance of diabetes in the applicant’s life. The awards are to be used for education, tennis development and/or medical care.
The recipients of the $5,000 national scholarships will receive their awards at a World TeamTennis Pro League match in July 2011 from WTT co-founder Billie Jean King. The scholarship program was established by King, through WTT Charities, in 1998 to encourage children with diabetes to lead an active life and compete in tennis.
The Novo Nordisk Donnelly Awards are named after two long-time World TeamTennis executives and tennis champions, Diane Donnelly Stone and Tracey Donnelly Maltby, who are sisters. Stone was an All-American and NCAA doubles champion at Northwestern University, and Maltby earned All-Big Ten honors at the University of Iowa. Both women have lived successfully with diabetes since childhood.
Novo Nordisk, a world leader in diabetes care, has been the title sponsor of the award since 2002. For more details on the Novo Nordisk Donnelly Awards and to download an application form, visit www.WTT.com/DonnellyAwards. For more information, contact Diane Donnelly Stone at email@example.com or 212-586-3444, x. 20.
About Novo Nordisk:
Novo Nordisk is a global healthcare company with more than 88 years of innovation and leadership in diabetes care. The company also has leading positions within hemophilia care, growth hormone therapy and hormone therapy for women. Novo Nordisk’s business is driven by the Triple Bottom Line: a commitment to social responsibility to employees and customers, environmental soundness and economic success. Headquartered in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchange in Copenhagen and its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk-us.com. For information about Novo Nordisk insulin products, visit novonordiskcare.com.
TIMag.com news search
Latest TIMag.com news
- ASICS launches BZ100 racquet
- Djokovic: 'Player of the Year'
- ASBA honors distinguished facilities
- Former pros set to compete
- Carson and Longoria sweep pro stops
- Fish receives ITA award
- Longoria sweeps gold
- Hourglass Performance Institute joins PTR
- Kid named sales manager for Volkl
- adidas introduces the Barricade 2015